Skip to main navigation Skip to search Skip to main content

R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts

  • Zhiyan Silvia Liu
  • , Sayantani Sinha
  • , Maxwell Bannister
  • , Axia Song
  • , Erica Arriaga-Gomez
  • , Alexander J. McKeeken
  • , Elizabeth A. Bonner
  • , Benjamin K. Hanson
  • , Martina Sarchi
  • , Kouhei Takashima
  • , Dawei Zong
  • , Victor M. Corral
  • , Evan Nguyen
  • , Jennifer Yoo
  • , Wannasiri Chiraphapphaiboon
  • , Cassandra Leibson
  • , Matthew C. McMahon
  • , Sumit Rai
  • , Elizabeth M. Swisher
  • , Zohar Sachs
  • Srinivas Chatla, Derek L. Stirewalt, H. Joachim Deeg, Tomasz Skorski, Eirini P. Papapetrou, Matthew J. Walter, Timothy A. Graubert, Sergei Doulatov, Stanley C. Lee, Hai Dang Nguyen

Research output: Contribution to journalArticlepeer-review

Abstract

RNA splicing factor (SF) gene mutations are commonly observed in patients with myeloid malignancies. Here we showed that SRSF2- and U2AF1-mutant leukemias are preferentially sensitive to PARP inhibitors (PARPi), despite being proficient in homologous recombination repair. Instead, SF-mutant leukemias exhibited R-loop accumulation that elicited an R-loop-associated PARP1 response, rendering cells dependent on PARP1 activity for survival. Consequently, PARPi induced DNA damage and cell death in SF-mutant leukemias in an R-loop-dependent manner. PARPi further increased aberrant R-loop levels, causing higher transcription-replication collisions and triggering ATR activation in SF-mutant leukemias. Ultimately, PARPi-induced DNA damage and cell death in SF-mutant leukemias could be enhanced by ATR inhibition. Finally, the level of PARP1 activity at R-loops correlated with PARPi sensitivity, suggesting that R-loop-associated PARP1 activity could be predictive of PARPi sensitivity in patients harboring SF gene mutations. This study highlights the potential of targeting different R-loop response pathways caused by spliceosome gene mutations as a therapeutic strategy for treating cancer.

Original languageEnglish (US)
Pages (from-to)577-597
Number of pages21
JournalCancer Research
Volume84
Issue number4
DOIs
StatePublished - 2024

Bibliographical note

Publisher Copyright:
©2023 American Association for Cancer Research.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription–Replication Conflicts'. Together they form a unique fingerprint.

Cite this